INTRODUCTION
T HE SEQUENCING OF THE HUMAN GENOME has led to the identification of thousands of novel genes whose functions are unknown or poorly defined. In an attempt to understand the activities of these genes, functional genomic technologies are emerging that allow for the high-throughput screening (HTS) of gene products using cellular systems. 1 Developing reproducible and robust functional assays that are predictive of disease processes is critical for the discovery of new drug targets. Furthermore, understanding the involvement of newly identified genes in the intracellular signaling pathways that drive these disease processes is necessary for drug target validation.
The vascular endothelium plays a crucial role in the pathogenesis of a variety of disease processes and is a major target for the actions of an assortment of cytokines and growth factors. For instance, the inflammatory response and vascular injury are integrally regulated by the actions of tumor necrosis factor α (TNFα ) on vascular endothelial cells. 2 In addition, the vascular endothelial growth factors (VEGFs) can largely regulate the formation of new blood vessels, a process that is critical for the pathogenesis of such diseases as cancer, chronic inflammatory diseases, and diabetic retinopathy. 3 As would be expected, antagonizing the pathways elicited by TNFα and VEGF has immense therapeutic potential and is a major undertaking of the pharmaceutical industry. Although current therapeutics are focused primarily on inhibition at the level of the ligand or receptor, 4, 5 identifying novel targets in these pathways may provide better points for therapeutic intervention.
In this article, we describe 2 assays for identifying gene products modulating VEGF and TNFα signaling pathways in human endothelial cells. The assays make use of real-time quantitative PCR to monitor the transcriptional readout of pathway-driven reporter genes. As opposed to conventional fluorescent-or luminescent-based transcriptional reporter gene assays, our system does not require the production of stable cell lines expressing a given reporter construct and can be used with primary cell types. Using adenoviral-mediated gene delivery as an overexpression approach, we have adapted these assays to screen for novel modulators of the VEGF and/or TNFα pathways. in endothelial growth medium (EGM, Cambrex) containing defined supplements (CC-4133). They were incubated at 37°C in 5% CO 2 . Wortmannin, SB203580, and VEGF receptor 2 kinase inhibitor I were purchased from Calbiochem. PD98059 was purchased from Cell Signaling Technology. Recombinant human VEGF-165 and TNFα were purchased from R&D Systems. Custom recombinant adenoviruses were constructed by Galapagos Genomics BV (Mechelen, Belgium). The adenoviruses were assembled using IntroGene's patented PER.C6 ™ /AdApt ™ adenoviral technology. Recombinant adenoviruses expressing IκB kinase (IKK2) wildtype and dominant-negative alleles were kindly provided by Dr. Hae Lim (Pharmacia).
Adenoviral infection and cytokine stimulation of HUVEC
Viruses were titered using the Ad-Q PCR method. 6 Briefly, this method is based on the quantitative PCR amplification of a 77-bp fragment in the 5′ end of the adenovirus type 5 genome, which can be used to rapidly determine physical titers of the adenoviral genome. Viruses were diluted to a working titer of 1.2 × 10 9 viral particles/mL in adenovirus dilution buffer (Dulbecco's modified Eagle's medium [DMEM] + 0.1% bovine serum albumin [BSA]). Subconfluent HUVEC were counted and plated at 5000 cells/well in 96-well culture plates and subsequently infected 2 to 3 h later at a multiplicity of infection (MOI) of 5000 (= 5000 viral particles/ cell).
After a 24-h infection, HUVEC were washed with serum-free EBM and starved for 18 h in EBM containing 0.1% fetal bovine serum. For assays measuring tissue factor mRNA transcript, cells were subsequently stimulated for 1 h with 10 ng/mL of human VEGF, unless otherwise noted. For measurement of Intercellular Adhesion Molecule-1 (ICAM-1) transcript, cells were subsequently stimulated for 8 h with 5 ng/mL of human TNFα, unless otherwise noted.
Following cytokine stimulation, HUVEC were lysed and processed for mRNA extraction using either the mRNA Catcher kit (Sequitur, Inc., 7001) or the GenePlate kit (RNAture, 21GP02-1). The mRNA was eluted in 50 µL total volume.
Primer and probe design
Primers and probes for β-glucuronidase (GUS), tissue factor, and ICAM-1 were designed using Primer Express 2.0 (Applied Biosystems). Primers were designed such that their amplicon spanned at least 1 intron/exon boundary to ensure that no contaminating genomic DNA was amplified in the PCR product. The quencher dye on the probes was Minor Groove Binder/Non-Fluorescent Quencher (MGBNFQ). All primers were synthesized by BioSource International with its EconoPure method, and probes were synthesized by Applied Biosystems.
The primer/probe set for GUS was forward, 5′-TGGTT GGAGAGCTCATTTGGA-3′; reverse, 5′-GCACTCTCGTCGG TGACTGTT-3′; and probe, 5′-(VIC)-TTTGCCGATTT CATGACT-(MGBNFQ)-3′. The primer/probe set for ICAM-1 was forward, 5′-GCCAGGAGACACTGCAGACA-3′; reverse, 5′-TGGCTTCGTCAGAATCACGTT-3′; and probe, 5′-(6FAM, 6-carboxyfluorescein)-ACCATCTACAGCTTTCCGGCGC-(MGBNFQ)-3′. The primer set for tissue factor was forward, 5′-TTTCAGTGTTCAAGCAGTGATTCC-3′, and reverse, 5′-GACCACAAATACCACAGCTCCAA-3′.
Real-time PCR and relative mRNA quantitation
Quantitative real-time PCR (RT-PCR) was carried out by a 1step method using the ABI Prism 7000 Sequence Detection System and SYBR Green reagents (Applied Biosystems). Detection of PCR products was monitored by measuring the increase in fluorescence resulting from the binding of the double-stranded DNA binding dye, SYBR Green, and threshold cycles (C T ) were subsequently determined. Using the above primer pair sets, the relative efficiencies of the target and reference amplifications were determined to be approximately equal over a 125-fold range in the RNA template, and the absence of nonspecific amplification was confirmed by dissociation curve analysis. Relative quantitation of gene transcripts was carried out by the comparative C T method, and results are expressed as relative expression values (= 2 -∆∆CT ). Calculation of this value involved normalizing target gene expression levels to the housekeeping gene, GUS, and comparing normalized target expression in test samples to the normalized target expression in unstimulated samples.
RT-PCR reactions were carried out using Applied Biosystems protocols and reagents. Reactions were carried out in a total volume of 25 µL with the following components: 1× SYBR Green PCR Master Mix, 6 U MultiScribe reverse transcriptase, 10 U RNase inhibitor, primer pair sets, and 10 µL of mRNA template. Primers were used at the following final concentrations: GUS, 50 nM forward primer, 50 nM reverse primer; ICAM, 50 nM forward primer, 50 nM reverse primer; and tissue factor, 50 nM forward primer, 350 nM reverse primer. Cycling parameters were as follows: 48°C for 30 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min, followed by a dissociation curve analysis.
Quantitative determination of ICAM-1 transcript levels was also carried out by a 1-step multiplex method involving the amplification of ICAM-1 and GUS transcripts within the same reaction. In this case, RT-PCR products were detected by the 5′ nuclease reaction, using Applied Biosystems TaqMan reagents. Reactions were similarly carried out in a total volume of 25 µL with the following components: 1× AmpliTaq Gold DNA Polymerase Master Mix, 1× Multiscribe RT Enzyme Mix, 350 nM GUS forward primer, 350 nM GUS reverse primer, 100 nM GUS probe, 150 nM ICAM-1 forward primer, 150 nM ICAM-1 reverse primer, 100 nM ICAM-1 probe, and 10 µL of mRNA template. Multiplex reactions were cycled at 48°C for 30 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min.
Transcriptional-Based, Functional Genomics Assays

RESULTS
Tissue factor and ICAM-1 as transcriptional readouts
The transcriptional regulation of tissue factor and ICAM-1 mRNA expression in endothelial cells by VEGF and TNFα, respectively, has been extensively reported. 7, 8 Whereas regulation of tissue factor expression at the transcriptional level by VEGF is dependent on the transcription factor EGR-1, 9,10 ICAM-1 transcriptional induction by TNFα is dependent on nuclear factor-κB (NF-κB). 11 We selected these gene transcripts as potential readouts of VEGF and TNFα signaling cascades due to the robust inductions of these transcripts previously observed and the understanding of their transcriptional elements. [9] [10] [11] In addition, these transcriptional pathways have been implicated in functionally relevant cellular responses mediated by VEGF and TNFα. 2, 12 To measure the VEGF-or TNFα-mediated induction of these transcripts, we miniaturized the assay into a 96-well plate format that involved seeding 5000 HUVEC and isolating polyA mRNA in a high-throughput microplate format ( Fig. 1 ). Tissue factor or ICAM-1 mRNA transcript expression levels could be subsequently quantified by RT-PCR (ABI, Sequence Detection System). Data analysis involved normalizing the target mRNA expression levels to that of a reference transcript, GUS, to alleviate potential differences in the total amount of mRNA added to each reaction. In addition, target expression levels were compared "relative" to target levels in unstimulated HUVEC, using the wellestablished comparative C T method.
To optimize conditions for monitoring tissue factor and ICAM-1 mRNA transcript levels, we examined expression of these transcripts at various time points following VEGF and/or TNFα stimulation in HUVEC. As shown in Figure 2A , VEGF can stimulate the rapid induction of the tissue factor mRNA transcript that consistently reaches optimal expression levels at 60 min following VEGF treatment. In a dose-dependent manner, VEGF can stimulate up to approximately 100-fold increases in the relative expression level of the tissue factor mRNA transcript at this time point (Fig. 2B ). The kinetics of ICAM-1 induction differs, with optimal expression levels detected at 8 h following TNFα stimulation ( Fig.  2C ). Although TNFα stimulates the dose-dependent induction of the ICAM-1 mRNA transcript to approximately 100-to 200-fold relative expression levels ( Fig. 2D ), VEGF is unable to induce the ICAM-1 mRNA transcript at any time point examined (Fig. 2C ). Constitutive tissue factor and ICAM-1 expression levels were not altered over the time courses examined (data not shown). For purposes of assay development, we selected the 1-h and 8-h time points for assessing tissue factor and ICAM-1 mRNA transcripts, respectively ( Fig. 1 ).
Validation of transcriptional assays using kinase inhibitors
The regulation of tissue factor activity by VEGF has been shown to involve both positive and negative signaling events. Whereas the p38 and ERK-1/2 mitogen-activated protein (MAP) kinases have been shown to be critical for upregulating tissue factor activity by VEGF, the phosphatidylinositol 3 (PI3)-kinase pathway can play an inhibitory role. 13 Specifically, activating the PI3-K pathway by overexpressing constitutively active Akt (myr-Akt) can lead to the reduction in VEGF-stimulated tissue factor activity, and blocking the PI3-K pathway with chemical inhibitors can enhance VEGF-stimulated tissue factor activity. Due to the complex nature of tissue factor regulation by VEGF, we sought to validate our assay using compounds modulating both upstream and downstream components of the reported pathways. As shown in Figure 3A , a chemical inhibitor of VEGF receptor 2 can block the VEGF-stimulated induction in the tissue factor mRNA transcript in a dose-dependent manner. Furthermore, we could suppress the VEGF-mediated induction of tissue factor mRNA using 2 different MAP kinase pathway inhibitors (SB203580 and PD98059) at the identical molar concentrations as previously reported for inhibiting tissue factor activity 13 (Fig. 3B ). Conversely, an inhibitor of the PI3-K pathway, wortmannin, augmented VEGF-stimulated tissue factor mRNA expression above the level detected in control-treated (untreated, DMSO) cultures. Therefore, consistent with our understanding of the pathways regulating the VEGF-tissue factor pathway, we observed clear effects on tissue factor mRNA transcript expression using tool compounds in our assay.
Use of adenoviral-mediated gene delivery
Broad tissue tropism and high transduction efficiencies make recombinant adenoviruses an effective means of delivering gene products. HUVEC are particularly amenable to adenovirus type 5 infection, with 100% transduction efficiencies detected at a MOI as low as 1000 viral particles/cell. 14 Therefore, we tested this approach to examine the effects of replication-defective, recombinant type 5 adenoviruses that direct expression of known mediators of the VEGF and TNFα pathways in HUVEC. In particular, wild-type and/or dominant-negative alleles of VEGF receptor 2 (FLK) and IκB kinase 15 (IKK2) were used to modulate the VEGF and TNFα pathways, respectively. HUVEC were preinfected with recombinant adenoviruses for 24 h prior to serum starvation, cytokine stimulation, and harvest ( Fig. 1) . We found that a 24-h preinfection with 1000 to 5000 MOI resulted in strong expression of adenoviral-delivered gene products at both the transcript and protein levels (data not shown). As controls, adenoviruses expressing either no gene product (empty) or β-galactosidase (lacZ) were tested and shown to have no appreciable effect on VEGFstimulated tissue factor or TNFα-stimulated ICAM-1 mRNA expression compared to uninfected HUVEC (data not shown; see Fig. 4C ). As depicted in Figure 4A ,B, overexpression of dominant-negative alleles of VEGF receptor 2 (FLK_dn) and of IκB kinase (IKK2_dn) inhibited the cytokine-driven induction of tissue factor and ICAM-1 mRNA transcripts, respectively, in a dose-dependent manner. FLK_dn overexpression had no significant effect on tissue factor expression in unstimulated HUVEC but resulted in the nearly complete inhibition in VEGF-stimulated tissue factor expression at a MOI of 1000 ( Fig. 4A) . Similar results were observed with the IKK2_dn adenovirus, in which the complete inhibition of TNFα-stimulated ICAM-1 transcript was detected at an MOI of 500, with no effect on ICAM-1 levels in unstimulated HUVEC (Fig. 4B) . The opposite effect on transcript levels was observed on overexpression of wild-type alleles. Specifically, overexpression of wild-type IKK2 (IKK2_wt) could induce the expression of ICAM-1 mRNA expression in unstimulated HUVEC but had no effect on the expression of ICAM-1 in the presence of TNFα (Fig.  4B) . Similarly, overexpression of the wild-type FLK construct resulted in a 42-fold induction in the relative expression of tissue factor mRNA in unstimulated HUVEC (data not shown). Thus, the cytokine-driven induction of reporter transcripts could be specifically modulated through the adenoviral-mediated expression of known signaling intermediates.
To further demonstrate the specificity of inhibiting transcriptional responses with the use of recombinant adenoviruses, Changes in VEGF-stimulated tissue factor expression upon kinase inhibition were statistically significant (p = 0.002, SB203580; p = 0.017, PD98059; p = 0.006, wortmannin). we examined tissue factor mRNA expression regulated by different stimuli. In addition to VEGF, the inflammatory cytokines TNFα and IL-1 are well-known inducers of tissue factor expression. 16 We have found that TNFα stimulates a slightly stronger induction in tissue factor mRNA transcript compared to VEGF, but the kinetics are identical (see Fig. 4C ; data not shown). The adenoviral-mediated overexpression of FLK_dn can inhibit VEGF-stimulated induction of the tissue factor mRNA transcript but had no appreciable effect on TNFα-stimulated tissue factor expression (Fig. 4C) . Conversely, overexpression of IKK2_dn resulted in a strong inhibition in tissue factor expression stimulated by TNFα but not by VEGF. A control adenovirus expressing the lacZ gene product had no effect on tissue factor expression induced by either stimulus. Thus, these data further validate the use of adenoviral-mediated gene expression as a means to specifically modulate these transcriptional pathways.
Screening an arrayed adenoviral library
To identify novel modulators of these VEGF-and TNFαmediated pathways, we used an arrayed adenoviral cDNA library that encodes primarily wild-type and enzymatically inactive alleles of novel kinase and phosphatase genes that was constructed as previously described. 14 A total of 350 adenoviruses were screened at an MOI of 5000 on multiple assay plates, as outlined in Figure 1 . To normalize results between assay plates, tissue factor and ICAM-1 expression levels were compared relative to expression in cytokine-stimulated, control empty virus-infected cultures on each assay plate. HUVEC infected with FLK_dn and/or IKK2_dn adenoviruses were run as additional controls in each experiment. The combined results of these screens are presented in Figure 5 . In general, overexpression of FLK_dn and IKK2_dn resulted in 93% and 96% reductions of the respective cytokinedriven reporter gene, as denoted by the filled diamonds on the yaxis. We defined an assay hit as any adenoviral-expressed gene product that resulted in a ≥ 50% reduction in VEGF-stimulated tissue factor or TNFα-stimulated ICAM-1 expression, and we identified 11 and 2 gene products capable of negatively modulating the respective pathways. This corresponded to a hit rate of 3.1% and 0.6% for these assays. As an example of an assay hit, an adenovirus overexpressing the angiopoietin-1 gene product (see asterisk, Fig.  5A ) resulted in a 66% reduction in VEGF-stimulated tissue factor expression. Interestingly, angiopoietin-1 was previously reported to negatively regulate both the expression and activity of tissue factor by VEGF in endothelial cells, 17 thus providing further validation of this system as a target discovery tool.
In addition, we were able to identify assay hits that cooperated with VEGF and/or TNFα to stimulate additional increases in reporter gene transcripts. In particular, we identified 8 and 15 adenoviral-expressed gene products that were able to stimulate 3fold or greater increases in the VEGF-or TNFα-driven reporter genes, respectively. However, many of these gene products were able to induce the expression of constitutive tissue factor and/or ICAM-1 mRNA expression, independent of cytokine stimulation (data not shown). Not surprisingly, several of these adenoviruses encoded wild-type kinases known to activate MAP kinase signaling cascades.
DISCUSSION
In this report, we have described the development and utilization of 2 high-throughput assays that make use of quantitative PCR technology to measure transcriptional readouts of the VEGF and TNFα pathways. These transcriptional readouts were extremely robust, with approximately 100-fold changes in gene expression detected upon stimulation with the respective cytokines. Furthermore, minor differences in mRNA transcript levels could be accurately and reproducibly determined by the real-time quantitative PCR system used. These assays provide several key advantages over conventional transcriptional reporter assays that exploit specific promoter elements fused to a reporter gene. 18 In particular, such assays require extensive knowledge of the transcriptional regulatory elements and promoters for construction of reporter constructs, which is not necessary for our assays. In addition, our assays do not require the use of cell lines that express the reporter gene construct in a stable manner. The stable expression of reporter gene constructs is often problematic in many cell types (including primary cells), and there are additional labor and time constraints to producing and maintaining such cell lines. Finally, we can minimize potential differences in reporter gene readouts that could occur due to minor alterations in cell number or RNA recovery because the described assay normalizes target mRNA levels to that of an endogenous control transcript. Accounting for such differences is not possible with the conventional reporter assays that require a one-time enzymatic readout of reporter gene activity. Thus, the assays described in this article provide several advantages over other high-throughput, transcriptional-based screening technologies.
Our assays also offer vast improvements over other cell-based HTS assays measuring VEGF-and/or TNFα-dependent functions. In particular, developing high-throughput, cell-based assays for measuring VEGF-dependent functions has been especially challenging. Cell-based HTS assays for VEGF receptor drug discovery have focused primarily on VEGF-dependent cellular receptor phosphorylation and cellular proliferation, despite the extremely low signal-to-noise ratio. 19, 20 Often, lower-throughput cellular assays are used to further validate the specificity and potency of identified compounds. However, with such a robust signal-to-noise ratio (see Fig. 2 ), the VEGF transcriptional assay described here offers a viable alternative to other VEGF-dependent, cell-based HTS assays. Also, demonstration of the dose-dependent inhibition of this VEGF-dependent activity using a commercial VEGF receptor 2 compound inhibitor (Fig. 3A ) further supports this assay as a useful drug discovery tool.
High-throughput cellular screening formats for measuring TNFα-driven responses are more readily available. In particular, the detection of TNFα-stimulated ICAM-1 by enzyme-linked immunosorbent assay (ELISA) time-resolved fluorimetry and luminescence-based reporter systems has been reported in endothelial HTS assays. [21] [22] [23] However, the time-resolved fluorimetry and luminescent reporter assays provide much lower signal-tonoise ratios compared to our assay (~4-to 8-fold and 3-fold, respectively). [22] [23] [24] Although the immunological detection of cell surface ICAM-1 by conventional ELISA is a more robust assay, 21 it does not provide any potential multiplexing capabilities that would be obtainable with real-time PCR.
In addition to the potential utilization of these assays for drug discovery applications, they offer a powerful tool for identifying novel targets modulating VEGF and TNFα pathways. These assays were particularly amenable to an adenoviral-mediated gene delivery approach, as we did not detect any deleterious effect of the adenovirus on these reporter gene transcripts. This was verified by the inability of the control (empty, lacZ) viruses to significantly alter reporter transcripts relative to uninfected cells (Fig. 4) , as well as by the low hit rate observed in the screen of 350 recombinant adenoviruses ( Fig. 5 ). Most important, we used this approach to identify both known and novel gene products that could modulate the VEGF-driven and TNFα-driven transcriptional responses. Overexpression of dominant-negative kinases that are well-established signaling intermediates of the respective pathways can inhibit cytokine-driven transcriptional responses. Moreover, we detected a known inhibitor of the VEGF/tissue factor pathway, angiopoietin-1, 17 from the random screen of the adenoviral cDNA library. Angiopoietin-1 was previously reported to inhibit VEGFmediated tissue factor activity through the intracellular activation of the PI3 kinase/Akt, 17 which is consistent with the observed effect of the PI3 kinase inhibitor on tissue factor mRNA expression ( Fig. 3B ). Several novel gene products were also identified that suppressed these cytokine-stimulated pathways, although further validation studies are required to characterize the involvement of these novel gene products on VEGF and TNFα signaling cascades. Regardless, modulation of VEGF and TNFα reporter genes with known regulators of the respective pathways validates the fidelity and utility of these assays for novel target discovery.
